Cargando…

Impact of UGT1A1 genotype on the efficacy and safety of irinotecan‐based chemotherapy in metastatic colorectal cancer

The phase III AXEPT study showed the noninferiority of modified capecitabine plus irinotecan (mXELIRI) with or without bevacizumab relative to fluorouracil, leucovorin, and irinotecan (FOLFIRI) with or without bevacizumab as a second‐line treatment for metastatic colorectal cancer. We evaluated the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iwasa, Satoru, Muro, Kei, Morita, Satoshi, Park, Young Suk, Nakamura, Masato, Kotaka, Masahito, Nishina, Tomohiro, Matsuoka, Hiroshi, Ahn, Joong Bae, Lee, Keun‐Wook, Hong, Yong Sang, Han, Sae Won, Cho, Sang‐Hee, Zhang, Dong‐Sheng, Fang, Wei‐Jia, Bai, Li, Yuan, Xiang‐Lin, Yuan, Ying, Yamada, Yasuhide, Sakamoto, Junichi, Kim, Tae Won
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586680/ https://www.ncbi.nlm.nih.gov/pubmed/34327766 http://dx.doi.org/10.1111/cas.15092

Ejemplares similares

Impact of prior chemotherapy with two different fluoropyrimidines on the efficacy of capecitabine plus irinotecan or FOLFIRI with or without bevacizumab in metastatic colorectal cancer: a post hoc analysis of the AXEPT study
por: Iwasa, Satoru, et al.
Publicado: (2023)

Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab
por: Kotaka, Masahito, et al.
Publicado: (2016)

UGT1A1 polymorphisms in cancer: impact on irinotecan treatment
por: Takano, Masashi, et al.
Publicado: (2017)

A novel system for predicting the toxicity of irinotecan based on statistical pattern recognition with UGT1A genotypes
por: TSUNEDOMI, RYOUICHI, et al.
Publicado: (2014)

Predictive Value of UGT1A1*28 Polymorphism In Irinotecan-based Chemotherapy
por: Liu, Xing-Han, et al.
Publicado: (2017)

The association between UGT1A1 polymorphisms and treatment toxicities of liposomal irinotecan
por: Su, Y.-Y., et al.
Publicado: (2022)

Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1
por: de With, Mirjam, et al.
Publicado: (2023)

UGT1A1 polymorphisms in rectal cancer associated with the efficacy and toxicity of preoperative chemoradiotherapy using irinotecan
por: Kimura, Kei, et al.
Publicado: (2018)

Relationship between UGT1A1*27 and UGT1A1*7 polymorphisms and irinotecan‐related toxicities in patients with lung cancer
por: Fukuda, Minoru, et al.
Publicado: (2017)

Differences in UGT1A1, UGT1A7, and UGT1A9 Polymorphisms between Uzbek and Japanese Populations
por: Maeda, Hiromichi, et al.
Publicado: (2014)

UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer
por: Marcuello, E, et al.
Publicado: (2004)

Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer
por: Fujii, Hironori, et al.
Publicado: (2018)

The relationship between UGT1A1 gene polymorphism and irinotecan effect on extensive-stage small-cell lung cancer
por: Xiao, Xiao-guang, et al.
Publicado: (2015)

Phenotyping of UGT1A1 Activity Using Raltegravir Predicts Pharmacokinetics and Toxicity of Irinotecan in FOLFIRI
por: Lee, Lawrence Soon-U, et al.
Publicado: (2016)

Dosage Adjustment of Irinotecan in Patients with UGT1A1 Polymorphisms: A Review of Current Literature
por: Argevani, Lia, et al.
Publicado: (2020)

The UGT1A9*22 genotype identifies a high-risk group for irinotecan toxicity among gastric cancer patients
por: Lee, Choong-kun, et al.
Publicado: (2022)

Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancer
por: Li, Minmin, et al.
Publicado: (2014)

Molecular Genetics External Quality Assessment Pilot Scheme for Irinotecan-Related UGT1A1 Genotyping in China
por: Yi, Lang, et al.
Publicado: (2016)

Relationship between UGT1A1*6/*28 gene polymorphisms and the efficacy and toxicity of irinotecan-based chemotherapy
por: Bai, Yu, et al.
Publicado: (2017)

Rapid and sensitive detection of UGT1A1 polymorphisms associated with irinotecan toxicity by a novel DNA microarray
por: Tsunedomi, Ryouichi, et al.
Publicado: (2017)

Value of plasma SN-38 levels and DPD activity in irinotecan-based individualized chemotherapy for advanced colorectal cancer with heterozygous type UGT1A1(*)6 or UGT1A1(*)28
por: Tian, Chuan, et al.
Publicado: (2018)

Association of UGT1A1*6, UGT1A1*28, or ABCC2 c.3972C>T genetic polymorphisms with irinotecan‐induced toxicity in Asian cancer patients: Meta‐analysis
por: Atasilp, Chalirmporn, et al.
Publicado: (2022)

Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer
por: Jo, J-C, et al.
Publicado: (2012)

Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians
por: Liu, X, et al.
Publicado: (2014)

Life-Threatening Irinotecan-Induced Toxicity in an Adult Patient with Alveolar Rhabdomyosarcoma: The Role of a UGT1A1 Polymorphism
por: Jannin, Arnaud, et al.
Publicado: (2017)

Irinotecan dose reduction in metastatic colorectal cancer patients with homozygous UGT1A1*28 polymorphism: a single-center case series
por: Tsai, Hsiang-Lin, et al.
Publicado: (2022)

FOLFIRI and regorafenib combination therapy with dose escalation of irinotecan as fourth-line treatment for patients with metastatic colon cancer according to UGT1A1 genotyping
por: Lu, Chien-Yu, et al.
Publicado: (2014)

UGT1A1 Polymorphism for Irinotecan Dose Escalation in Patients with BRAF-Mutated Metastatic Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI
por: Hsieh, Yi-Chien, et al.
Publicado: (2021)

Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotecan plus 5-Fluorouracil/Leucovorin for Pancreatic Ductal Adenocarcinoma: A Multicenter, Retrospective Cohort Study (HGCSG2101)
por: Harada, Kazuaki, et al.
Publicado: (2023)

Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first‐line treatment for metastatic colorectal cancer: Safety lead‐in results from the QUATTRO-II study
por: Kotani, Daisuke, et al.
Publicado: (2021)

UGT1A1(*)28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study
por: Kweekel, D M, et al.
Publicado: (2008)

Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang
por: Chen, Shaojun, et al.
Publicado: (2020)

UGT1A1 polymorphism has a prognostic effect in patients with stage IB or II uterine cervical cancer and one or no metastatic pelvic nodes receiving irinotecan chemotherapy: a retrospective study
por: Matsuoka, Hideki, et al.
Publicado: (2020)

Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial
por: Doi, Toshihiko, et al.
Publicado: (2018)

Clinical Implication of UGT1A1 Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated with Bevacizumab Combined with FOLFIRI in the First-line Setting()()
por: Lu, Chien-Yu, et al.
Publicado: (2015)

Impact of single-heterozygous UGT1A1 on the clinical outcomes of irinotecan monotherapy after fluoropyrimidine and platinum-based combination therapy for gastric cancer: a multicenter retrospective study
por: Nakano, Shintaro, et al.
Publicado: (2020)

Association between UGT1A1*28 Polymorphisms and Clinical Outcomes of Irinotecan-Based Chemotherapies in Colorectal Cancer: A Meta-Analysis in Caucasians
por: Liu, Xiang, et al.
Publicado: (2013)

Rapid detection of the irinotecan‐related UGT1A1*28 polymorphism by asymmetric PCR melting curve analysis using one fluorescent probe
por: Kong, Xiaomu, et al.
Publicado: (2022)

An expansion study of genotype-driven weekly irinotecan and capecitabine in combination with neoadjuvant radiotherapy for locally advanced rectal cancer with UGT1A1 *1*1 genotype
por: Guan, Yun, et al.
Publicado: (2019)

Establishment of UGT1A1-knockout human iPS-derived hepatic organoids for UGT1A1-specific kinetics and toxicity evaluation
por: Shintani, Tomohiro, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_u026ohftlvs8so5nta74mor1nq